Table 1 Characteristics of included patients in our cohort
Characteristics | n (%) |
|---|---|
Total | 54 (100) |
Age at start of osimertinib, years | |
 Median (range) | 58 (31–83) |
  < 60 | 29 (53.7) |
  ≥ 60 | 25 (46.3) |
Sex | |
 Female | 35 (64.8) |
 Male | 19 (35.2) |
Smoker | |
 Never | 40 (74.1) |
 Ever | 11 (20.4) |
 Unknown | 3 (5.6) |
Histology | |
 Adenocarcinoma | 52 (96.3) |
 Adenosquamous carcinoma | 2 (3.7) |
Brain metastases | |
 Yes | 26 (48.1) |
 None | 28 (51.9) |
Line of therapy | |
 1st/2nda | 38 (70.4) |
 3rd or more | 16 (29.6) |
NGS platform | |
 BGIb | 29 (53.7) |
 OrigiMed | 25 (46.3) |
EGFR activating mutation | |
 Exon 19 deletion | 40 (74.1) |
 Exon 21 L858R | 14 (25.9) |
TP53 status | |
 Mutated | 33 (61.1) |
 Wild type | 21 (38.9) |